Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-10-09
2007-10-09
Bragdon, Kathleen Kerr (Department: 1656)
Chemistry: molecular biology and microbiology
Vector, per se
C435S325000, C530S350000
Reexamination Certificate
active
10355218
ABSTRACT:
The present invention relates to the identification of novel biologically active compounds having an agonist or an antagonist effect on the transcriptional-activating activity of the Estrogen-Related Receptor 3 (ERR3).
REFERENCES:
patent: 5579250 (1996-11-01), Balaji et al.
patent: 5642292 (1997-06-01), Itai et al.
patent: WO98/56812 (1998-12-01), None
patent: WO 00/26365 (2000-05-01), None
Coward, P. et al. P. Natl. Acad. Sci. USA., vol. 98., pp. 8880-8884, 2001.
Rollerova et al. Intracellular Estrogen Receptors, Their Characterization and Function (Review). Endocrine Regulations. 2000. vol. 34, pp. 203-218.
Bohm et al. The Computer Program LUDI: A New Method for the de novo Design of Enzyme Inhibitors. Journal of Computer-Aided Molecular Design. 1992. vol. 6, pp. 61-78.
Goodsell et al. Automated Docking of Flexible Ligands: Applications of AutoDock. Journal of Molecular Recognition. 1996. vol. 9, pp. 1-5.
Dean, P.M., Recent Advances in Drug Design Methods: Where Will They Lead? BioEssays, 1994. vol. 16, No. 9, pp. 683-687.
Shiau, Andrew et al.: “The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen”,Cell, vol. 95, No. 7, Dec. 23, 1998, pp. 927-937, XP-002248698.
Ashley, C.W. Pike, “A structural biologist's view of the oestrogen receptor”, Journal of Steroid Biochemistry and Molecular Biology, vol. 74, No. 5, 2000, pp. 261-268, XP-002248699.
Tanenbaum, David M. et al.: “Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains”, Proceedings of the National Academy of Science, vol. 95, May 1998, pp. 5998-6003, XP-002222196.
Lewis, David F.V. et al.: “Molecular Modelling of the Human Estrogen Receptor and Ligand Interactions Based on Site-directed Mutagenesis and Amino Acid Sequence Homology”, Journal of Steroid Biochemistry and Molecular Biology, vol. 52, No. 1, 1995, pp. 55-65, XP-002248700.
Wurtz, Jean-Marie et at.: “Three-Dimensional Models of Estrogen Receptor Ligand Binding Domain Complexes, Based on Related Crystal Structures and Mutational and Structure-Activity Relationship Data”, Journal of Medicinal Chemistry, vol. 41, No. 11, May 1998, pp. 1803-1814, XP-002200987.
Gangloff, M. et al.: “Crystal Structure of a Mutant hERα Ligand-binding Domain Reveals Key Structural Features for the Mechanism of Partial Agonism”, Journal of Biological Chemistry, vol. 276, No. 18, May 4, 2001, pp. 15059-15065, XP-002248701.
Brzozowski, Andrzej M. et al.: “Molecular basis of agonism and antagonism in the oestrogen receptor”, vol. 389, No. 6652, 1997, pp. 753-758, XP-002248702.
Norris, John D. et al.: Peptide Antagonists of the Human Estrogen Receptor, Science, vol. 285, No. 5428, Jul. 30, 1999, pp. 744-746, XP-002248703.
Greschik, Holger et al.: “Structural and Functional Evidence for Ligand-Independent Transcriptional Activation by the Estrogen-Related Receptor 3”, Molecular Cell, vol. 9, No. 2, Feb. 2002, pp. 303-313, XP-002248704.
Greschik Holger
Moras Dino
Renaud Jean-Paul
Wurtz Jean-Marie
Bragdon Kathleen Kerr
Centre National de la Recherche Scientifique "CNRS"
Noakes Suzanne M.
Young & Thompson
LandOfFree
Method for identifying antagonist compounds of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying antagonist compounds of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying antagonist compounds of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3902146